Unfortunately, esophageal perforations, fistulas and leaks are not "infrequent" conditions. As pointed by Goenka et al. [@JR1184-1] in a recent review article, perforation, fistula and leak are terms that are often used interchangeably but, in strict terms, they are completely different. Perforation is defined as an acute full thickness defect; leak is defined as a disruption of a surgical anastomosis resulting in a fluid collection; and fistula is defined as an abnormal communication between two epithelialized surfaces.

In this issue of Endoscopy International Open, Ojima et al. [@JR1184-2] publish an original article evaluating the efficacy and safety of endoscopic injections of alpha-cyanoacrylate monomer in 25 patients with intractable esophageal "fistulas" secondary to esophageal surgery. This study, although interesting and necessary, incorrectly uses the term fistula instead of leak and, indeed, patients with esophagotracheal fistulas were excluded from the study. This has important significance in terms of efficacy and safety.

It is well-known that leaks are usually the step prior to fistula development and that they usually close better and earlier. On the other hand, endoscopic injection of tissue sealants is probably safer in leaks than in fistulas. In the leak scenario, the glue excess would usually reach a cavity while in the fistula scenario, it would reach the airway, leading to respiratory or pulmonary complications. Management of leaks and fistulas is quite similar but not equal in terms of timing, techniques, follow-up and outcomes. Therefore, the results of Ojima et al. [@JR1184-2] should be taken into account only in patients with esophageal leaks and not those with fistulas.

The prevalence of gastrointestinal leaks has increased in recent years, probably due to the increasing complexity of both surgery and endoscopic interventions. In fact, they are usually secondary to esophagogastric surgery. In a recent multicenter registry that included 2704 esophagectomies, anastomotic leaks occurred in 11.4 % of cases [@JR1184-3] but prevalence has been reported to be up to 50 % [@JR1184-4] . Because esophageal leaks are associated with high morbidity and mortality rates -- up to 80 % if an esophago-respiratory fistula develops -- they should be considered potentially life-threatening events and treatment should be immediate to avoid severe consequences such as mediastinitis, pneumonia and other fatal events [@JR1184-5] [@JR1184-6] . In fact, in a recent study, early stent insertion was identified as a significant independent predictor of successful sealing and thus, morbidity reduction [@JR1184-7] .

Treatment of anastomotic leak remains controversial, as the indications for surgical, conservative and endoscopic therapy remain non-standardized. Several options have been reported to treat esophageal leaks. On the one hand, the classic therapy is surgery. Surgical techniques and timing depend mainly on lesion nature, size, location, previous interventions and patient clinical status and normally include repair, esophagectomy or cervical exclusion together with drainage of mediastinal and peritoneal contamination if present. However, despite continuous surgical advances, the mortality rate for re-intervention is still high [@JR1184-8] . The main reason for the "poor numbers" for surgery in this scenario is that most patients who undergo reintervention are in very poor physical and nutritional condition due to concomitant infections as well as absence of oral feeding. Thus, surgery should be considered as the last treatment step and reserved to those refractory cases.

Conceptually, the endoscopic approach is faster, less invasive and can be easily repeated in case of non-response. In recent years, development of new endoscopic devices, concepts and techniques has led to new therapeutic options, resulting in several published reports of successful interventions in this clinical scenario. Current endoscopic techniques for esophageal leaks include self-expandable stents, usually as the first-line option (metallic, plastic and biodegradable) and clips (both through-the-scope and over-the-scope clips), suturing devices, tissue sealants and endoscopic vacuum therapy as second-line alternatives [@JR1184-1] [@JR1184-9] [@JR1184-10] [@JR1184-11] [@JR1184-12] [@JR1184-13] [@JR1184-14] [@JR1184-15] [@JR1184-16] . Surprisingly, all of them, used alone or combined, have been demonstrated to be "almost perfect" since 80 % to 90 % of leaks were successfully repaired. However, these cases have been published as case reports or in small series. So, to date, the quality of evidence is very low and does not allow for following/giving any strong recommendation. On the other hand, endoscopists have the perception that literature "numbers" in these setting do not reflect outcomes in daily practice. Therefore, larger series of endoscopic therapy for esophageal leaks are welcome to give us "light in darkness."

Ojima et al. [@JR1184-2] report complete closure of leaks in 22 of 25 patients, which means a success rate of 88 % with no complications and/or recurrence. The authors conclude that these results suggest that alpha-cyanoacrylate injection could be a good therapeutic option in these patients. Moreover, alpha-cyanoacrylate monomer may work even better than the classic n-butyl 2-cyanoacrylate or 2-octyl cyanoacrylate polymers due to some advantages such as its stronger adhesive and antibacterial properties. Finally, the authors comment that a large multicenter, randomized, double-blind, placebo-controlled phase III clinical trial is planned to prove the clinical application of their proposal.

To our knowledge, this is one of the largest series of endoscopic therapy of esophageal leaks, and no doubt, using cyanoacrylate. The complete leak closure rate reported by Ojima et al. [@JR1184-2] , although excellent, is somewhat optimistic because they considered both leak reduction and complete closure as successful treatments. On the other hand, there are no data regarding patient clinical outcome in terms of symptom relief and proper long-term follow-up. So, the authors should have concluded that endoscopic injection of alpha-cyanoacrylate monomer is effective in the short term in reducing/closing esophageal leaks after surgery. Anyway, these numbers together with those of similar studies [@JR1184-1] [@JR1184-12] [@JR1184-13] are good enough to consider endoscopic cyanoacrylate injection as a valid therapeutic alternative in this clinical scenario. Advantages of cyanoacrylate injection are costs, safety profile and the possibility of using it in combination with other techniques while the disadvantages are the number of sessions needed -- up to 14 in the study of Ojima et al. [@JR1184-2] -- and poor outcomes in leaks greater than 10 mm.

So, what therapy should we choose? Because there are no comparative studies between the different endoscopic alternatives, it is difficult to establish a therapeutic algorithm in these patients. Determining the optimal therapy for such patients requires: 1) careful examination of patient clinical status; 2) intensive examination of the anastomotic defect by means of chest computed tomography, x-ray barium/gastrografin study and upper endoscopy; and 3) a review of all available options, local expertise and previous experience. It is important to remember that the approach to esophageal leaks should always be individualized and multidisciplinary.

Based on literature data and as a general rule, fully/partially covered self-expandable metallic stents (SEMS) should be the first-line option for esophageal leaks except in patients who have poor-response predictors, such as failure at first attempt, fistula development, leak greater than 20 mm and/or poor clinical status as demonstrated by two recent papers [@JR1184-17] [@JR1184-18] . Due to the high migration rate for stents -- up to 26 % [@JR1184-19] -- use of anchoring systems such as clips or suturing devices are highly recommended to keep the stents "on site" closing the defect as much as needed. Usually, 4 to 8 weeks should be enough. In situations in which SEMS are likely to fail [@JR1184-17] [@JR1184-18] , the "other" endoscopic alternatives should be taken into account, those being tissue sealants and endoscopic vacuum therapy, the most promising options.
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